Background
==========

Non-invasive, 24-hour ambulatory blood pressure monitoring (ABPM) has emerged as an important instrument assisting clinicians in the diagnosis and management of hypertension. Although several studies have validated the prognostic significance of data acquired from ABPM; historically, access to the technology in the United States is generally limited to specialty referral clinics such as cardiology or nephrology, found in larger teaching institutions \[[@B1]-[@B4]\]. The limited access in primary care offices is probably due, in part, to the lack of reimbursement by most medical insurance companies for the procedure. Thus, the routine use of the technology in primary-care offices is somewhat of a novelty.

However, the landscape of ABPM in the United States is currently shifting. Recent prospective outcome studies have fueled the argument that ABPM should play a more prominent role in the diagnosis and management of the hypertensive patient \[[@B5]\]. The Joint National Committee of the National High Blood Pressure Education Program and the British Hypertension Society recommend its use in a number of clinical scenarios, while other organizations have cautiously endorsed its use \[[@B6]-[@B11]\]. Although some experts question the cost-effectiveness of routine use of ABPM in hypertensive patients \[[@B12]\], others have proclaimed that judicious ABPM use can actually decrease cost of care \[[@B13],[@B14]\]. When available, ABPM appears to be well-accepted by physicians \[[@B15]\].

With recent accumulating evidence supporting the role of ABPM in clinical practice, the United States Centers for Medicare and Medicaid Services (CMS) now reimburses for the testing in patients with suspected white-coat hypertension \[[@B16]\]. Because a significant number of patients with hypertension are insured by Medicare, it is likely that the demand for ABPM services will increase, and this shift will occur in primary care clinics \[[@B17]\]. Several prior studies have examined utilization of ABPM in clinical practice; that is, reasons why physicians order the test and how the results of the test influence decision-making \[[@B18]-[@B20]\]. While these studies have documented the physician use and acceptance of ABPM technology, none of the studies examined patient satisfaction associated with use of ABPM in this setting. Furthermore, improved microelectronic and battery technology have allowed the equipment to become more compact and lightweight in the last 10 years, increasing portability and perhaps comfort.

Patients undergoing ABPM testing are required to wear the device for 24-hours, during which time the monitor records blood pressure at regularly programmed intervals \[[@B17]\]. Since patients are asked to go about their normal daily activities while wearing the monitor, it is probable they will experience some discomfort during the session and anticipation of this discomfort may negatively influence their acceptance of undergoing the testing, and possibly their acceptance of any pharmacologic interventions which might result from the testing. Because limited information exists in the medical literature on this topic, and particularly lacking in the primary care setting, the purpose of this report is to describe our primary care clinic\'s experience with patient acceptance of ABPM.

Methods
=======

Description of the ABPM Service
-------------------------------

The ABPM service is located within the University of Iowa Family Care Center. The Family Care Center serves nearly 60,000 patient visits yearly between its Family Medicine and Internal Medicine outpatient clinics. The ABPM service is co-directed by a board-certified family physician (GB) and a clinical pharmacist who is a board-certified pharmacotherapy specialist (ME).

Primary care physicians who, in the course of a routine office visit determine that ABPM is clinically indicated in the management of their patient, refer the patient to the service. The patient returns to the clinic on a different day to have the monitor fitted by the clinical pharmacist, and returns the monitor the next day after completing the 24-hour testing period. The data from the monitor is then downloaded into a software program for data analysis. The report is initially reviewed by the clinical pharmacist, with particular reference to the effects of any medications, then the results are forwarded to the ordering physician for final review and action.

SpaceLabs Medical, Inc. (Redmond, WA) 90207 Ultralite ABP monitors are used by the service. The computer software program used is the ABP Report Management System, version 1.03.11 from SpaceLabs Medical, Inc., which provides a printout of all blood pressures, including summary statistics for mean blood pressures and blood pressure load for daytime, nighttime and overall 24 hours. The service began in January 2001 and follow-up for this study represents data accrued through July 31, 2003. The study was approved by the University of Iowa institutional review board.

Patient Satisfaction Survey
---------------------------

Consecutive patients referred for ABPM testing by their primary care provider were asked to complete a 9-item questionnaire regarding their experience with ABPM, upon completion of the 24-hour ABPM session (see Additional File 1). The questionnaire was anonymous and if patients did not return the survey, they were not contacted with a follow-up reminder. Patients who were referred for a follow-up ABPM session were only surveyed once.

The questionnaire asked for responses to the following questions regarding the ABPM session, using a five point Likert scale ranging from \"strongly agree\" to \"strongly disagree\": *\"My doctor clearly explained the benefit of undergoing this testing;\" \"Wearing the monitor for 24 hours was not uncomfortable;\" \"Considering the monetary and time cost to me, I think undergoing ambulatory blood pressure monitoring was worthwhile;\" \"I think information provided by the test will be helpful in making decisions about how to treat my blood pressure;\"*and, *\"Overall, I am very satisfied with my experience.\"*The other four questions on the survey asked specifically about the physical resources of the ABPM service, such as location and staff involved, and were included for quality assurance purposes. Thus, their responses are not relevant to this analysis. Finally, space was given on the survey for any additional comments patients wished to include. These comments were aggregated into major themes.

The data obtained from the survey were entered into a spreadsheet and frequency distributions and descriptive statistics were used to summarize the data. For analysis purposes, responses of \"neutral\" were considered to be a negative response and grouped with the \"disagree\" and \"strongly disagree\" responses as a more conservative method of assessing satisfaction, while \"strongly agree\" and \"agree\" responses were combined. Comparisons between the groupings were assessed via chi-square analysis.

Results
=======

Two hundred forty-five ABPM sessions were performed between January 1, 2001 and July 31, 2003. Ten patients had two or more ABPM sessions during this period, reducing the number of eligible participants surveyed to 235. Of these, 177 returned patient satisfaction surveys yielding a final response rate of 75%.

Because the survey was anonymous, the demographic data represent the demographics of the 245 patients who completed at least one ABPM session, not just the responders to the survey. The mean age of the ABPM participants was 52.6 years (range 17--86; std. dev 16.3), and just over half (51%) of the patients were male (Table [1](#T1){ref-type="table"}). While Family Medicine physicians ordered more of the ABPM sessions (n = 137/245; 56%) than Internal Medicine physicians, the indications for ordering the test were not different between the two groups (chi-square, p = 0.13).

###### 

Demographics of the population undergoing ABPM testing one or more times during the analysis period (n = 245).

  --------------------------------------------------- -------------
  Age (in years)                                      
   Mean ± SD                                          52.6 ± 16.3
   (Range)                                            (17--86)
  Gender                                              
   Female                                             119 (49%)
   Male                                               126 (51%)
  Indication for ABPM^a^                              
   Evaluation of blood pressure control               71 (29%)
   Borderline hypertension^b^                         62 (25%)
   Suspected white-coat hypertension                  60 (24%)
   Treatment resistance                               19 (8%)
   Other                                              33 (13%)
  Outcome Resulting from ABPM^a^                      
   Medication initiated                               51 (21%)
   Diagnosed white-coat hypertension                  49 (20%)
   No change in therapy (blood pressure controlled)   37 (15%)
   Medication changed                                 31 (13%)
   Dose/regimen adjusted                              21 (9%)
   Recommend lifestyle modifications                  14 (6%)
   Other/unknown                                      42 (18%)
  --------------------------------------------------- -------------

^a^categories are mutually exclusive ^b^defined as those patients with office blood pressures that are elevated into the Stage 1 range at some visits, but also in the pre-hypertension range (per JNC-VII classification -- ref. \[[@B10]\]) at other visits. These patients are untreated and have not been officially diagnosed with hypertension.

The most frequent indication (n = 71; 29% of patients) for undergoing ABPM testing was to evaluate blood pressure control on current antihypertensive therapy, followed by evaluation of borderline office hypertension (n = 62; 25% of patients), and suspected white-coat hypertension in an untreated patient (n = 60; 24% of patients). The most common management outcome resulting from the data obtained from the ABPM test was the initiation of an antihypertensive agent (n = 51; 21% of patients). White-coat hypertension was diagnosed in 20% of the patients. Overall, the ABPM sessions were well-tolerated, with only 3 patients failing to wear the device for the entire testing period. Complications, such as petichiae at the cuff site, or arm thrombosis, were not reported by any of the patients.

Patient satisfaction was generally high with ABPM in this setting. Of the 177 surveys returned, 75% (n = 132/177) of patients reported that the twenty-four hour ABPM test was worthwhile when considering the time and monetary cost of the session. Most patients (n = 132/177; 90%) thought the test results would provide information that would help their physician make treatment decisions. Overall, most patients (n = 157/177; 89%) reported being satisfied with their ABPM experience.

Despite the overall positive patient perceptions of ABPM, some patients voiced dissatisfaction with the comfort of ABPM. Twenty percent (n = 36/177) of patients reported that the ABPM session was uncomfortable, while another 28% (n = 50/177) responded neutrally to the statement. However, when asked about whether the test results would provide useful information in helping make treatment decisions, the 86 patients who rated ABPM as uncomfortable or neutral were just as likely to report that they believed the test would provide useful information to help make treatment decisions, as the 89 patients who reported no discomfort from the test (chi-square; p = 0.07).

A second area of dissatisfaction reported by patients was related to whether their physician clearly explained the benefit of undergoing the testing. Seventeen (7%) patients did not feel that their physician had clearly explained the benefit of undergoing the testing. Additionally, 30% of these patients reported they did not think the results of the ABPM testing would be helpful in making treatment decisions. In contrast, of the 159 (90%) patients who reported that their physician had clearly explained the benefit of undergoing the testing, only 6% reported they did not think the results of the test would be helpful (chi-square; p \< 0.01). Further analysisofthe patients who reported that their physician did not clearly explain the benefit of the testingfound a trend forreporting greater discomfort with the test (chi-square; p = 0.11)compared to patients who reported they were satisfied with their physicians\' explanations of the benefit of undergoing the testing.

Finally, in the open ended general comment section, 43 patients provided content which were organized into 4 general themes: (1) problems with the ABPM session (e.g., physical discomfort; difficulty performing normal daily activities; difficulty sleeping); (2) perceived benefit of undergoing the testing (e.g. unsure what useful information would be obtained) (3) ease of testing (e.g. surprised at how easy the test was); and, (4) miscellaneous (e.g. scheduling, fitting of monitor, etc.). The most common written comment, mentioned by 24 patients, pertained to the ABPM device and problems encountered while performing activities of daily living and sleep. However, 9 patients noted the test was easier than expected and that the information should be helpful in making treatment decisions.

Discussion
==========

Over a two-and-a-half-year period, patients undergoing ABPM in a primary care office setting in the United States reported that this method of testing was well-accepted and tolerated. The most common complaint was about discomfort while undergoing the testing but only 20% of patients reported this trouble. Additionally, even those patients who offered this complaint generally felt the test was worthwhile.

Although ABPM recordings are considered more reliable than office or home blood pressure measurements, there is a trade-off between patient comfort and accuracy with ABPM. Our data indicate that patients generally believe the results will be helpful in making treatment decisions and are willing to be inconvenienced by an ABPM session. We also found that thephysician\'s effectiveness in explaining the need for ABPM testingto a patientis linked to the patients\' perception of the study. Thus, physicians should clearly explain the benefit of undergoing ABPM testing to their patients when it is ordered.

Our findings about patient satisfaction with ABPM are the first reported in a population from the United States, a country where ABPM is generally not reimbursed, and routine use of ABPM in clinical practice is the exception and not the norm. Our results are consistent with those described in a recent qualitative study of ABPM in Great Britain \[[@B21]\]. In this study, patient preferences for different methods of measuring blood pressure (home, ambulatory, nurse, doctor) in the primary care setting were compared, and it was concluded that respondents felt all methods were worth the trouble to get accurate measurements \[[@B21]\]. However, home blood pressure monitoring has limitations which include lack of recording during sleep hours, an important time period for obtaining data which may have value for prognosis, as well as questionable accuracy as patients may not record their blood pressures faithfully \[[@B22],[@B23]\]. Although ambulatory measurements were noted in the study findings to have higher likelihood of discomfort and disturbance of life and sleep compared to the other methods of measurement, it was otherwise well-accepted by patients. Our findings are fairly similar; this similar level of acceptance is notable given the differencesinuse of ABPM and how medical care is financedin Great Britain compared to the United States.

Aside from the study by Little et al. \[[@B21]\], there is a modest amount of other information about patient satisfaction with ABPM. Acceptability and tolerance of ABPM was evaluated in a study by Mallion et al. based on a case series of 672 patients \[[@B24]\]. Problems that patients encountered while undergoing ABPM included those related to the cuff pressure (32%), awkwardness of the machine (14%) and noise of the monitor (6%). Sleep disturbances were reported by 55% of patients, although only 14% of patients reported more than 3 awakenings. However, this study differed from ours and could be subject to bias since the physician ordering the test actually filled out the survey after asking the patient a series of questions upon completing the ABPM session. Furthermore, the study was performed in French cardiologist offices using older ABPM equipment. Thus, it unlikely that these findings apply to a primary care population in the United States undergoing ABPM using current technology.

Our study must be interpreted within the context of several important limitations. The demographics reported represent the entire population completing ABPM, not just the survey responders; thus, no information is known about survey non-reponders and how their experience with ABPM compared. However, our response rate was very high, which increases the generalizability of our data and suggests we have accurately assessed the perceptions of patients undergoing ABPM within our setting. Secondly, our study was conducted at one site, so geographical differences in practice styles might be a consideration. However, our site is a typical primary care setting in the United States, and to our knowledge the study is the first to examine patient satisfaction with ABPM in this setting. This is important since ABPM is likely to transition from being used almost exclusively in specialty referral clinics to more widespread use in primary care settings. Lastly, it is known that physician approach can often influence patient behavior. We did not provide suggested language to physicians for how to explain to the patient the rationale and need for ordering the test. It is possible that confusion on the part of the uninformed patient might then have influenced survey responses, although our study reflects how the test would likely be ordered in usual practice.

In spite of these limitations, our survey provides useful information regarding patient acceptance of modern ABPM testing in a primary care setting in the United States. Because of its proven utility in the clinical setting, and recent CMS approval for coverage in patients with suspected white coat hypertension, demand for the ABPM testing in the future is likely to shift predominantly from specialty referral centers to primary care offices.

Conclusions
===========

When clinically appropriate, clinicians should not hesitate to order ABPM for fear of subjecting their patient to potential discomfort, and they should be sure to educate the patient about the potential benefits of undergoing the testing. Despite in many cases being an uncovered insurance benefit, patients generally believe the test will provide useful information in making treatment decisions, and appear willing to experience some discomfort in the process.
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